Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNotes PayablesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal Liabilities
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Universe Pharmaceuticals (UPC) Retained Earnings (2021 - 2025)

Universe Pharmaceuticals' Retained Earnings history spans 4 years, with the latest figure at -$10.2 billion for Q3 2024.

  • For Q3 2024, Retained Earnings fell 428674.83% year-over-year to -$10.2 billion; the TTM value through Sep 2024 reached -$10.2 billion, down 428674.83%, while the annual FY2024 figure was -$10.2 billion, 428674.83% down from the prior year.
  • Retained Earnings for Q3 2024 was -$10.2 billion at Universe Pharmaceuticals, down from -$2.4 million in the prior quarter.
  • Across five years, Retained Earnings topped out at $16.3 million in Q3 2022 and bottomed at -$10.2 billion in Q3 2024.
  • The 4-year median for Retained Earnings is -$141740.5 (2021), against an average of -$2.5 billion.
  • The largest annual shift saw Retained Earnings skyrocketed 681.44% in 2022 before it tumbled 428674.83% in 2024.
  • A 4-year view of Retained Earnings shows it stood at $2.1 million in 2021, then surged by 681.44% to $16.3 million in 2022, then crashed by 114.53% to -$2.4 million in 2023, then crashed by 428674.83% to -$10.2 billion in 2024.
  • Per Business Quant, the three most recent readings for UPC's Retained Earnings are -$10.2 billion (Q3 2024), -$2.4 million (Q3 2023), and $16.3 million (Q3 2022).